EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Brepocitinib in patients with active noninfectious uveitis: Results from the Phase 2 NEPTUNE trial

Quan Dong Nguyen, Mark Dacey, Robert Wang, Dilraj S. Grewal, Kelly L. Larkin, Edmund Tsui, Akshay Thomas, Christopher R. Henry, David S. Chu, Steven Yeh, Stephen Anesi, James T. Walsh und 19 weitere

AJO International · 2026-12 · 3 (4) · 100332

DOI: 10.1016/j.ajoint.2026.100332 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AJO International, 2026-12. Verfasst von Quan Dong Nguyen und 30 weiteren Autor:innen. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the efficacy and safety of brepocitinib, an oral, selective tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1) inhibitor, in adults with active NIU.

Design

NEPTUNE was a 52-week, phase 2, multicenter, double-masked, randomized, dose-ranging clinical trial conducted in the United States between November 2022 and July 2024. Participants were randomized 2:1 to receive brepocitinib 45 mg or 15 mg once daily. All participants underwent an accelerated protocol-mandated glucocorticoid taper, with discontinuation of systemic and topical steroids by Week 8. Subjects Adults between the ages of 18 and 74 with active NIU were eligible for enrollment. Intervention and Methods Participants received oral brepocitinib 45 mg or 15 mg once daily. The primary efficacy outcome was the proportion of participants experiencing treatment failure (TF) by Week 24, which was compared with a prespecified historical placebo rate of 80%. Additional outcomes included TF through Week 52 and effects on visual acuity, ocular inflammation, and macular edema. Safety was assessed in all participants who received at least one dose of brepocitinib.

Results

Twenty-six participants (mean age, 42 years; 65% female) were enrolled. By Week 24, TF occurred in 29.4% (95% CI, 10.3–56.0) of participants receiving brepocitinib 45 mg and 44.4% (95% CI, 13.7–78.8) receiving brepocitinib 15 mg, reflecting significant reductions relative to the prespecified historical placebo rate (P

Zitieren

APA

Nguyen, Q. D., Dacey, M., Wang, R., Grewal, D. S., Larkin, K. L., Tsui, E., Thomas, A., Henry, C. R., Chu, D. S., Yeh, S., Anesi, S., Walsh, J. T., Hassman, L. M., Shah, R., Amini, P., Kwun, R. C., Edwards, A., Raiji, V., Cogollos, A. S., …, & Foster, C. S. (2026). Brepocitinib in patients with active noninfectious uveitis: Results from the Phase 2 NEPTUNE trial. AJO International, 3(4), 100332. https://doi.org/10.1016/j.ajoint.2026.100332

Vancouver

Nguyen QD, Dacey M, Wang R, Grewal DS, Larkin KL, Tsui E, et al. Brepocitinib in patients with active noninfectious uveitis: Results from the Phase 2 NEPTUNE trial. AJO International. 2026;3(4):100332. doi:10.1016/j.ajoint.2026.100332

BibTeX
@article{Nguyen2026,
  author = {Nguyen, Quan Dong and Dacey, Mark and Wang, Robert and Grewal, Dilraj S. and Larkin, Kelly L. and Tsui, Edmund and Thomas, Akshay and Henry, Christopher R. and Chu, David S. and Yeh, Steven and Anesi, Stephen and Walsh, James T. and Hassman, Lynn M. and Shah, Rajiv and Amini, Payam and Kwun, Robert C. and Edwards, Albert and Raiji, Veena and Cogollos, Ana Suelves and Toy, Brian C. and Rifkin, Lana and Crowell, Eric L. and Gangaputra, Sapna and Sharma, Sumit and Thorne, Jennifer E. and Suhler, Eric and Shaw, Katharina S. and Johnson, Brendan and Cascino, Matthew D. and Hajj-Ali, Rula A. and Foster, C. Stephen},
  title = {Brepocitinib in patients with active noninfectious uveitis: Results from the Phase 2 NEPTUNE trial},
  journal = {AJO International},
  year = {2026},
  volume = {3},
  number = {4},
  pages = {100332},
  doi = {10.1016/j.ajoint.2026.100332}
}
Kostenlos starten →